Deal signings surge, but revenue stays flat—what's really happening at Birlasoft
TCV jumped 20% YoY while revenue inched up just 0.3% in constant currency. Management blames AI-driven pricing pressure, but the call revealed vague timelines on margin recovery and vertical turnarounds that institutional investors are already pricing out.
$168.7M
+20% YoY
+0.3%
After contraction; magnitude weak
16.1%
Normalized; wage hikes will dilute Q2
Birlasoft posted a clean quarter on the headline: ₹1,379 crore revenue (+7.4% YoY), ₹161 crore PAT (+51.3% YoY), 16.1% EBITDA margins. But the earnings call exposed a different story. Deal signings jumped 20% YoY to $168.7 million, yet revenue inched up just 0.3% in constant currency. Management's explanation—clients are demanding AI-driven productivity gains baked into deal pricing upfront—is honest, but it also signals a deflationary cycle Birlasoft can't control. The market reacted sharply on day 1 (+3.75%), but institutional flows tell the real verdict: FII and DII both trimmed positions QoQ despite the headline strength.
The TCV-to-revenue gap: where pricing pressure is hiding
Management's core claim—that "momentum is building"—rests on deal signings: $168.7 million TCV, up 20% YoY from Q1 FY26. That's real. But a 20% surge in deal value converting into 0.3% QoQ revenue growth in constant currency is not a sign of health. It's evidence that average deal economics have compressed. When asked directly, the CEO (Angan Guha) admitted that clients are pushing back: "Enormous amount of pressure in terms of pricing only because a lot of the work that we are now delivering, we are delivering using AI tools. Pricing pressure, there is a pressure to bake in that productivity." This is not temporary. Management says the mismatch will "take a couple of quarters to streamline," but elsewhere forecasts "over next 3–4 quarters expect convergence as industry stabilizes." That's a long runway during which TCV growth won't flow through to the P&L.
Enormous amount of pressure in terms of pricing only because a lot of the work that we are now delivering, we are delivering using AI tools. Pricing pressure, there is a pressure to bake in that productivity.
What management claimed vs. what holds up
EBITDA margins normalized to 16.1%
Delivered 16.1% OPM; prior Q4 had ~170 bps one-offs. July wage hikes (170–200 bps) will dilute Q2.
Supported, but forward risk
Deal signings $168.7M TCV, up 20% YoY
Correct. Q1 FY26 ≈ $140M. Growth real but off soft base; QoQ growth still 0.3% CC.
Supported, but misleading
Revenue momentum building in AI engagements
QoQ CC growth +0.3%, rupee +2.3%. Deal pipeline strong but revenue flat; pricing pressure acknowledged.
Overstated
Sales team expansion 30–40% by Q2 FY27
Priyank Chheda (Vallum Capital) challenged hard; actual headcount still below pre-COVID. Management walked back to 'process, couple of quarters.'
Contradicted
Manufacturing and E&U to recover by Q3
Both segments soft; management says 'couple quarters' but provides no firm booking trajectory or client spending indicators.
Partial (timeline non-binding)
What changed on this call
AI momentum elevated: Cogito MVP shown to 15+ clients; 25% of code via agentic AI; wins in FinServ, banking, pharma noted. Prior quarter vague.
Sales expansion delayed: Promised 30–40% by Q2 FY27 last quarter. Actual headcount still pre-COVID lows. Now 'process' and 'couple of quarters,' non-binding.
Vertical recovery extended: Manufacturing and E&U expected 'couple of quarters' to recover, but no firm order-book milestones disclosed. Uncertainty priced in by street.
Margin guidance hedged: Will 'push for 15%+ EBITDA' but wage hikes will dilute Q2 by ~85–100 bps (half the full impact). Recovery timing vague.
Capital allocation remains opaque: ₹2,878 crore cash (+26% YoY), largest on IT pack balance sheets. No buyback plan. M&A to focus on 'capability assets,' no ROIC threshold.
The market's verdict: initial pop fading on institutional selling
Birlasoft's result initially rallied hard—day 1 post-announcement saw a +3.75% pop with 52.4% delivery, suggesting short-covering and retail enthusiasm. But the rally stalled by day 3 (+0.83%) and only recovered to +7.77% by day 5. More tellingly, institutional ownership shifted away: FII trimmed 87 bps QoQ (13.65% → 12.78%), and DII cut 136 bps (23.35% → 21.99%), despite headline strength. The stock sits 34.17% below its all-time high (₹474 → ₹312.05), above its 20- and 50-day moving averages but well below the 200-day MA, with RSI at 64 (neutral zone). For a mid-tier IT services player claiming to be "AI First," that unwinding of institutional ownership in the quarters post-peak is a signal that large holders are unconvinced by the operational story. The tape agrees with the call: headline growth masks deflationary cycle and execution risk.
The bull-bear ledger
Deal pipeline momentum real: $168.7M TCV (+20% YoY) shows order book is building despite macro volatility.
AI platform roadmap concrete: Cogito MVP to 15+ clients, 25% of code via agentic tools, wins in BFSI/pharma validate early adoption.
Cash position strong: ₹2,878 crore (+26% YoY), DSO best-in-class at 55 days, OCF-to-EBITDA 108% signals clean generation.
Revenue growth stalled at 0.3% CC QoQ, weakest among large-cap IT services; TCV growth not translating due to pricing deflation.
Margin headwind material: July wage hikes (170–200 bps) will dilute Q2 P&L by ~85–100 bps. Recovery timeline vague; no guarantee on pace or magnitude.
Vertical concentration and weakness: 50% of revenue from Manufacturing and E&U, both soft for 2+ quarters; recovery 'couple quarters' but no firm booking trends disclosed.
Execution risk on sales expansion: Guided 30–40% headcount addition by Q2 FY27 last quarter. Priyank Chheda called out contradiction; management now says 'process.' Red flag on guidance credibility.
Capital allocation opaque: ₹2,878 crore cash (one-third of market cap) with no buyback or M&A plan disclosed. Board will 'look at' assets but no threshold or timeline. Shareholder value creation delayed.
Risks ranked by severity for a holder
Deflationary TCV-to-revenue cycle
HighClients demanding AI productivity gains baked into deal pricing upfront. TCV +20% but revenue +0.3% CC. Management says 'couple quarters' to streamline, elsewhere '3–4 quarters' to industry stabilization. Extended deflation will suppress P&L despite order book growth. Pricing power erosion is structural, not cyclical.
Vertical weakness (Manufacturing, E&U = 50% of revenue)
HighBoth soft for 2+ quarters. Recovery 'couple of quarters' or 'Q3 onwards' but no firm booking trajectory or client spending indicators disclosed. If recovery extends beyond Q3, full-year growth remains capped. Vertical concentration risk if turnaround stalls.
Margin dilution from wage hikes (170–200 bps from July)
MediumQ2 P&L expected to absorb ~85–100 bps dilution (half the full impact). Management expects 'productivity offsets' but offers no timeline or magnitude guarantee. If productivity gains don't materialize, full impact bleeds into H2, forcing margin guidance to reset lower.
Client concentration and breadth erosion
Medium36 accounts = 80% of revenue. Active accounts at 213 (lowest ever) despite account rationalization. New sales team expansion (30–40%) now delayed ('couple of quarters'). Limited new account pipeline and existing customer concentration limit upside, especially if top 36 has cyclic downturn.
AI capability unproven at scale
MediumCogito MVP shown to 15+ clients; 25% of code via agentic AI. Early-stage wins in BFSI, pharma, banking real. But no evidence of large-scale adoption, deal-size uplift, or margin premium vs. competitors. If AI differentiation doesn't drive pricing power or volume uplift over next 2–3 quarters, hype-to-execution gap widens.
Management guidance credibility erosion
MediumPriyank Chheda repeatedly challenged vague forward guidance: no revenue targets, no quantified deal pipeline, no H1 deal-signing commit, sales expansion timeline walked back from Q2 to 'couple quarters.' Analysts explicitly noted 'P&L momentum certainly not encouraging.' Lack of specific metrics weakens conviction that management can execute.
Capital allocation inertia
Low to Medium₹2,878 crore cash (one-third of market cap), highest on IT pack. No buyback, no M&A threshold, no timeline. Shareholder value creation delayed indefinitely. If capital sits idle while revenue growth stalls, ROE and returns on accumulated capital compress, warranting a lower valuation multiple.
What to watch next quarter (and H1)
1 · Q2 margin outcome vs. wage hike guidance
Management guided for ~85–100 bps dilution from the July wage hike to hit Q2 P&L, with expectation of recovery via productivity. If Q2 EBITDA margin falls to ~15.0–15.3%, the guidance holds. If it falls below 15.0%, or if management forecasts further delays in recovery, the wage offset thesis breaks and H2 guidance resets lower.
2 · H1 deal signings vs. prior year H1
Management committed to H1 deal signings being "much better" than prior year H1, but refused to quantify. If H1 FY27 deal TCV exceeds H1 FY26 by 25%, the pipeline momentum is real and the deflation-to-recovery timeline becomes credible.
3 · Manufacturing and E&U booking trends by Q3
Both verticals soft, comprising ~50% of revenue. Management expects recovery 'Q3 onwards' but offers no booking visibility. By Q3 guidance (or early Q3 pre-close commentary), track whether order book in these verticals is inflecting. If not, expect full-year revenue guidance to move down, and the vertical concentration risk becomes acute.
4 · Sales headcount additions and new account wins
Guided 30–40% sales team addition by Q2 FY27 last quarter. Priyank Chheda pressed hard; headcount still pre-COVID lows. By Q2 earnings, track actual salesforce headcount and number of new client wins. If additions remain slow and new account penetration stalls, the top-200-account expansion thesis fails, capping growth.
5 · Capital allocation announcement
Management is sitting on ₹2,878 crore cash. If Q2 or H1 update includes a buyback plan, M&A announcement, or dividend hike, the cash deployment risk lifts. If management remains silent, the inertia on capital allocation will continue to weigh on valuation multiple.
The debate
Birlasoft is not broken. But it's not yet fixed, either. The quarter delivered clean headline numbers and genuine deal momentum, but the earnings call stripped away the optics and exposed the true challenge: a company in the midst of a deflationary pricing cycle, with soft end-markets, wage headwinds, and vague management guidance. Institutional investors are already pricing this risk—FII and DII both trimmed this quarter despite the result pop. Until management proves it can deliver revenue growth and margin resilience through the wage-hike cycle and into H2, the stock is a 'show me' story. Watch Q2 margins, H1 deal signings, and Q3 vertical recovery trends. The debate resolves over the next two quarters.
Informational and educational content only. Not investment advice.